Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Natural Born Killers: NK Cells in Cancer Therapy
S. Elizabeth Franks, Benjamin Wolfson, James W. Hodge
Cancers (2020) Vol. 12, Iss. 8, pp. 2131-2131
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 111
The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer
Hans Klingemann
Cytotherapy (2023) Vol. 25, Iss. 5, pp. 451-457
Open Access | Times Cited: 63
Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
Bihui Cao, Manting Liu, Jingjun Huang, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 14, pp. 3850-3861
Open Access | Times Cited: 65
Strategies to enhance CAR-T persistence
Yue Liu, Lingna An, Ruihao Huang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 53
Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer
Mona M. Elanany, Dina Mostafa, Nadia Μ. Hamdy
Life Sciences (2023) Vol. 330, pp. 121997-121997
Closed Access | Times Cited: 41
A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer
Pengyu Yao, Liang Su, Zhenying Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
Kellsye P. Fabian, James W. Hodge
Molecular Therapy — Oncolytics (2021) Vol. 23, pp. 266-276
Open Access | Times Cited: 54
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Xiao Wang, Xuejiao Yang, Xiang Yuan, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 37
Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
Kangdi Yang, Yuze Zhao, Guanqun Sun, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 19
Heterodimeric IL-15 in Cancer Immunotherapy
Cristina Bergamaschi, Vasiliki Stravokefalou, Dimitris Stellas, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 837-837
Open Access | Times Cited: 35
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
Philipp Wendel, Lisa Marie Reindl, Tobias Bexte, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1481-1481
Open Access | Times Cited: 34
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
Wai Nam Liu, Wing Yan So, Sarah Harden, et al.
Science Advances (2022) Vol. 8, Iss. 47
Open Access | Times Cited: 28
DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study
Chiara Focaccetti, Monica Benvenuto, Chiara Pighi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma
Nathan Thomas Schomer, Ziyue Karen Jiang, Marit I. Lloyd, et al.
Cytotherapy (2022) Vol. 24, Iss. 8, pp. 827-834
Closed Access | Times Cited: 19
Lipid-mediated ex vivo cell surface engineering for augmented cellular functionalities
Sungjun Kim, Kyobum Kim
Biomaterials Advances (2022) Vol. 140, pp. 213059-213059
Closed Access | Times Cited: 19
Immunotherapies against HER2-Positive Breast Cancer
Santiago Duro‐Sánchez, Macarena Román Alonso, Joaquı́n Arribas
Cancers (2023) Vol. 15, Iss. 4, pp. 1069-1069
Open Access | Times Cited: 11
Adoptive NK cell therapy in AML: progress and challenges
Mona Rady, Maha Mostafa, Gabriel O. Dida, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Unveiling the Interplay Between Dendritic Cells and Natural Killer Cells as Key Players in Leishmania Infection
Ana Valério-Bolas, Mafalda Meunier, Armanda Rodrigues, et al.
Journal of Immunology Research (2025) Vol. 2025, Iss. 1
Open Access
CAR-T cells for cancer immunotherapy
Yangyang Xie, Xiaotong Li, Jingyi Wu, et al.
Chinese Chemical Letters (2023) Vol. 34, Iss. 9, pp. 108202-108202
Closed Access | Times Cited: 8
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Benjamin Wolfson, S. Elizabeth Franks, James W. Hodge
Vaccines (2021) Vol. 9, Iss. 5, pp. 509-509
Open Access | Times Cited: 18
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
Benjamin Wolfson, Michelle R. Padget, Jeffrey Schlom, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002258-e002258
Open Access | Times Cited: 18
Modulation of Immune Components on Stem Cell and Dormancy in Cancer
Xiaofan Jiang, Lu Liang, Guanglei Chen, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 2826-2826
Open Access | Times Cited: 18
Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future
Neda Minaei, Roya Ramezankhani, Atena Tamimi, et al.
European Journal of Cell Biology (2022) Vol. 102, Iss. 1, pp. 151284-151284
Open Access | Times Cited: 14
CAR-T Cells Targeting Immune Checkpoint Pathway Players
Vita Golubovskaya
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 4
Open Access | Times Cited: 13
Adoptive Cellular Transfer Immunotherapies for Cancer
Panagiotis Parsonidis, Ioannis Papasotiriou
Cancer Treatment and Research Communications (2022) Vol. 32, pp. 100575-100575
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top